U.S. Diversified Financial Stock News

If you are wondering whether Fidelity National Information Services is priced attractively right now, you are not alone. Many investors are asking if the current share price lines up with the company’s underlying value. The stock recently closed at US$64.23, with returns of a 4.2% decline over 7 days, a 4.3% decline over 30 days, a 2.1% decline year to date, a 16.2% decline over 1 year, and a 44.0% decline over 5 years, which may influence how you think about its potential and its...

Immunovant (IMVT) has been drawing attention after recent share moves that contrast a loss-making profile with fast annual growth in revenue and net income metrics, raising questions about how investors are weighing its clinical-stage risks. See our latest analysis for Immunovant. At a share price of $26.18, Immunovant’s recent 1 day share price return of 1.43% and 90 day share price return of 46.01% sit alongside a 1 year total shareholder return of 14.42% and 3 year total shareholder return...

If you are wondering whether J. M. Smucker's current share price fairly reflects its long term value, you are not alone. This article is built to unpack exactly that question. The stock last closed at US$101.61, with returns of 5.9% over the past 7 days, 5.2% year to date and 3.8% over the last year. The 3 year return sits at a 27.3% decline and the 5 year return at 3.7%. Recent coverage around J. M. Smucker has focused on its position in packaged foods and consumer staples, as investors...

JPMorgan Chase (JPM) has capped FY 2025 with fourth quarter revenue of US$41.1b and basic EPS of US$4.64, alongside net income of US$12.7b, setting a clear marker for how the bank is exiting the year. The company has seen revenue move from US$40.1b in Q4 2024 to US$41.1b in Q4 2025, while quarterly EPS went from US$4.82 to US$4.64 over the same period, giving you a clean year on year reference point for the top and bottom line. With trailing net profit margins sitting just below last year and...

If you are wondering whether CareTrust REIT's share price still offers value at around US$37.36, you are not alone; many investors are asking the same question. The stock has returned 1.9% over the last week, 2.9% over the last month, 2.9% year to date, 46.5% over the last year, 121.3% over three years, and 113.7% over five years. This naturally raises questions about what is already reflected in the price. Recent attention on CareTrust REIT has focused on its position within the healthcare...

If you are wondering whether CareDx at around US$20.19 is starting to look interesting again, you are not alone. This article is here to help you think through the value question. The share price has seen a 7.3% gain over the last week, while the 30 day return sits at a 1.8% decline and the 1 year return is a 8.4% decline. This is against a 42.3% gain over 3 years and a 78.4% decline over 5 years. Recent news coverage of CareDx has focused on how investors are reassessing the company in...

UBS’ decision to downgrade Perimeter Solutions (PRM) from Buy to Neutral, while the company funds its Medical Manufacturing Technologies acquisition through a $550 million note offering, has put the stock’s risk and return trade off in sharper focus. See our latest analysis for Perimeter Solutions. At a share price of $28.08, Perimeter Solutions has seen a 24.58% 3 month share price return and a 116.33% 1 year total shareholder return. This suggests recent momentum remains positive even as...

Wealthfront (WLTH) just posted its Q3 2026 numbers, with revenue of US$93.2 million, basic EPS of US$0.72 and trailing twelve month EPS of US$3.04 setting the backdrop for the quarter. The company has seen revenue move from US$80.3 million in Q3 2025 to US$93.2 million in Q3 2026, while quarterly EPS has shifted from US$0.77 to US$0.72 over the same period, against trailing twelve month revenue of US$351.5 million. With a current net profit margin of 35.2% versus 57.7% a year ago, this update...

Village Farms International (VFF) has drawn fresh attention after its Leli Holland unit rolled out ten new cannabis products into the regulated Dutch market, including the country’s first licensed blunt and several tailored spliff formats. See our latest analysis for Village Farms International. At a share price of $3.50, Village Farms International has seen a 30 day share price return decline of 14.22% and a year to date share price return decline of 5.15%. Its 1 year total shareholder...

3D Systems recently presented at the 28th Annual Needham Growth Conference while highlighting expanded Aerospace & Defense operations, new FDA clearance for its VSP Orthopedics platform, and balance-sheet strengthening through equity-funded debt reduction. Together, the push into defense-focused manufacturing, broader orthopedic indications, and efforts to reinforce the capital structure underscore how the company is repositioning around mission-critical, higher-value applications. We’ll now...

If you are wondering whether CoreCivic’s share price still offers value at around US$19.94, you are not alone. This article focuses squarely on what that price could mean for investors. The stock has returned 5.2% over the last 7 days, 5.5% over the last 30 days, 4.8% year to date, while its 1 year return of a 10.7% decline sits against a 76.8% return over 3 years and 173.9% over 5 years. Recent headlines around CoreCivic have continued to keep the company in focus, with investors weighing...

Delta Air Lines (DAL) has just wrapped up FY 2025 with Q4 revenue of US$16.0b and basic EPS of US$1.88, alongside net income excluding extra items of US$1,219m. Over the past year, revenue on a trailing twelve month basis moved from US$61.6b with EPS of US$5.39 to US$63.4b with EPS of US$7.72, while trailing net income excluding extra items rose from US$3,457m to US$5,005m. For investors, the current earnings outline a picture of firmer margins and profitability that now need to be weighed...

Autolus Therapeutics recently reported preliminary unaudited 2025 net product revenue of about US$75 million and issued 2026 guidance of US$120 million to US$135 million, alongside progressing obe-cel into Phase 2 trials for lupus nephritis and other indications. The company also secured UK and EU approvals for AUCATZYL®, pairing early commercial traction with expanding clinical data in both pediatric oncology and autoimmune disease. Next, we’ll examine how this combination of higher revenue...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

As the U.S. market navigates a landscape marked by fluctuating indices and inflation data that aligns with expectations, investors are keenly assessing the implications for high-growth sectors like technology. In this environment, identifying promising tech stocks involves evaluating companies that demonstrate resilience amidst economic shifts and possess innovative capabilities to capitalize on emerging opportunities.

As the U.S. stock market navigates through a landscape of record highs and inflationary pressures, investors are keenly assessing the implications of recent consumer price index data and corporate earnings reports. In this environment, identifying undervalued stocks requires a careful analysis of fundamentals and market sentiment, offering potential opportunities for those looking to capitalize on discrepancies between current valuations and intrinsic worth.

As the U.S. stock market navigates a period of cautious optimism following recent inflation data and mixed corporate earnings, investors are increasingly focused on identifying resilient growth opportunities. In this context, companies with high insider ownership often stand out as promising candidates, suggesting that those who know the business best have confidence in its future prospects.

As the U.S. stock market experiences a pullback with investors assessing CPI inflation data and major bank earnings, attention turns to alternative investment opportunities like penny stocks. Often considered an outdated term, penny stocks still hold relevance as they represent smaller or newer companies that can offer growth potential at lower price points. When these companies are backed by strong financial fundamentals, they present intriguing options for investors seeking hidden value in...

As the U.S. market navigates a landscape marked by recent inflation data and fluctuating key indices, investors are closely monitoring the performance of small-cap stocks within the S&P 600. With economic indicators showing resilience amid cautious optimism, identifying promising opportunities in lesser-known stocks can be crucial for those seeking to capitalize on potential growth. In this environment, a good stock often exhibits strong fundamentals and adaptability to changing economic...

Despite an already strong run, Planet Labs PBC ( NYSE:PL ) shares have been powering on, with a gain of 39% in the last...

In recent days, Wells Fargo and RBC Capital have each begun or renewed coverage of Phreesia, assigning favorable ratings that highlight its role as a healthcare technology provider with a SaaS-based patient intake platform. This wave of positive analyst attention points to growing institutional focus on how Phreesia’s software, used across thousands of physicians, could influence its growth profile and profitability efforts. Next, we’ll examine how this increase in supportive analyst...

UWM Holdings (UWMC) is back in focus after President Donald Trump announced a US$200b federal program to buy mortgage backed securities. The move is aimed at influencing mortgage rates outside the Federal Reserve’s actions. See our latest analysis for UWM Holdings. The news-driven jump in UWM’s share price sits against mixed recent performance, with a 20% 7 day share price return, a 21.09% year to date share price return, and a 68.11% 3 year total shareholder return. This suggests momentum...

Penske Automotive Group, Inc.'s ( NYSE:PAG ) price-to-earnings (or "P/E") ratio of 11.5x might make it look like a buy...

With no single headline event driving attention to McGraw Hill (MH) today, recent trading performance is doing the talking, including a past 3 months return of about 26% against a softer month and year to date. See our latest analysis for McGraw Hill. Short term, momentum has cooled with a 7 day share price return of 5.0% and a 30 day share price return of 7.7%. However, the 90 day share price return of 25.6% still points to building interest around McGraw Hill at a share price of $15.83. If...